Swiss Diabetes Venture Fund

What Swiss Diabetes Venture Fund does

Swiss Diabetes Venture Fund is europe’s first venture fund dedicated to diabetes technology.

Name

Swiss Diabetes Venture Fund

Legal name

Serpentine Ventures AG

Website

https://diabetesfund.vc/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Swiss Diabetes Venture Fund is a europe’s first venture fund dedicated to diabetes technology.

Ownership category

akta.pro rank

Product category

Venture Capital (Healthcare/Diabetes Technology)

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

Keywords

• Venture capital fund
• Diabetes technology investments
• Medtech venture capital
• Early-stage healthcare investing
• Specialist venture fund

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Core offering

The Diabetes Venture Fund is a venture capital fund that invests globally in early-stage diabetes technology startups. Managed by Serpentine Ventures AG (the investment arm of Swiss Ventures Group), the fund partners with the DCB (Diabetes Center Berne) to source proprietary deal flow and provide portfolio companies with medtech expertise, key opinion leader networks, corporate partners, and research facilities. The fund is available exclusively to professional and institutional clients.

Product overview

The Diabetes Venture Fund is a venture capital fund structure, not a product company. The fund offers venture capital investment services to professional and institutional investors, focused on early-stage diabetes technology startups globally. The portfolio consists of seven investee companies: BOYDSense (non-invasive blood glucose monitoring, France), GlucoSet (continuous glucose monitoring for ICU, Norway), Luna Health (overnight automated insulin delivery, US), OneTwo Analytics (AI-based CGM data analytics, Sweden), Piomic (chronic wound treatment, Switzerland), SNAQ (diabetes food tracker, Switzerland), and Supersapiens (glucose insights platform, US). These are separate legal entities in which the fund holds equity stakes, not products or modules of the fund itself.

Differentiator

Problem solved

Functional benefit

Products and services

• Diabetes Venture Fund Venture capital limited partnership offering institutional and professional investors specialized exposure to early-stage diabetes technology startups globally. Invests in companies across glucose monitoring, insulin delivery, AI-based CGM analytics, chronic wound treatment, and carbohydrate counting technology. Available exclusively to professional and institutional clients (not registered with FINMA). Closing in Q1 2026.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• DCB (Diabetes Center Berne)coreStrategic or Co-development PartnerDCB is a global center for technology innovation in diabetes, transforming diagnosis and treatment for people living with diabetes by addressing unmet needs. Simon Michel is Chair of DCB and Derek Brandt is CEO of DCB.
• Swiss Startup GroupminorStrategic or Co-development PartnerCompanies of the Swiss Startup Group are mentioned as subprocessors and data sharing partners in the privacy policy context.
• Invest EuropeminorOthersMember organization, logo displayed on website indicating professional industry membership.
• AbbottminorStrategic or Co-development PartnerAbbott provides the Libre Sense Glucose Sport Biosensor powering Supersapiens' continuous glucose monitoring digital platform. This is a partnership involving the portfolio company Supersapiens.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• JDRF T1D Fund: The venture philanthropy fund of JDRF (formerly Juvenile Diabetes Research Foundation), focused exclusively on Type 1 diabetes therapeutics and devices. It is the closest direct peer to Swiss Diabetes Venture Fund, sharing the disease-specific thematic VC model and serving similar early-stage diabetes technology companies globally.
• Ysios Capital: Spanish-based healthcare-focused venture capital firm with deep experience in diabetes, including investments in CGM and insulin delivery companies. Ysios is a comparable thematic healthcare VC operating in Europe with similar ticket sizes and stages to Swiss Diabetes Venture Fund.
• Omega Funds: Boston- and London-based healthcare-dedicated venture capital firm investing across life sciences including metabolic disease and diabetes technology. Comparable to Swiss Diabetes Venture Fund as a sector-focused mid-stage VC operating across US and Europe.
• Andera Partners (Life Sciences): European private equity firm with a dedicated Life Sciences practice that invests in medtech, biotech, and digital health including diabetes. Comparable in stage focus (Series A/B) and European footprint, frequently co-invests with thematic specialists in the same diabetes technology deals.

Broad incumbents

• Novo Seeds: The early-stage corporate venture arm of Novo Nordisk, focused on diabetes, obesity, and related cardiometabolic disorders. Comparable to Swiss Diabetes Venture Fund as a thematic diabetes investor with corporate backing, though it operates as part of a major pharma group rather than as a standalone sector-specialist fund.
• Roche Venture Fund: The corporate venture capital arm of F. Hoffmann-La Roche, investing in early-stage life sciences and diagnostics companies. While not diabetes-exclusive, it actively invests in diabetes diagnostics and digital health, overlapping with Swiss Diabetes Venture Fund's CGM analytics and monitoring portfolio companies.
• Sanofi Ventures: Sanofi's corporate venture capital arm invests in early-stage biotech and digital health, with diabetes as a strategic area. It is a larger, more generalist peer that competes for similar Series A/B healthcare technology deals.
• dRx Capital (Novartis): Novartis's digital health venture arm, investing in technology-enabled therapeutics and care delivery models including diabetes. Operates as a corporate strategic investor in the same therapeutic area as Swiss Diabetes Venture Fund, often co-investing in the same early-stage companies.
• Medtronic (Diabetes Strategic Investments): As a market leader in insulin pumps and CGM through its Diabetes business, Medtronic acts as a strategic acquirer and investor in diabetes technology startups. It is both a potential exit partner for Swiss Diabetes Venture Fund's portfolio and a competitor for sourcing the same deals.
• The Leona M. and Harry B. Helmsley Charitable Trust (Diabetes Program): The Helmsley Trust's Type 1 Diabetes Program funds venture, grant, and commercial-stage investments in diabetes technology and care. While not a traditional VC, it is one of the largest disease-focused capital allocators and a comparable thematic investor with similar deal-flow advantages in T1D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss Diabetes Venture Fund